Opportunity Overview
During infection, C. albicans can alter its morphology from yeast cells to invasive ‘pathogenic’ hyphae. However, the transition from yeast to hyphae is a tightly regulated process, and subject to environmental and genetic influences. Critically, clinical isolates of C. albicans often display a “spectrum of pathogenicity”, ranging from overtly pathogenic (producing invasive hyphae, invading tissues, and causing damage), to overtly commensal (producing no invasive hyphae and causing no tissue damage). These observations suggest that an additional level of regulation influences C. albicans pathogenicity.
C. albicans hyphae are ‘pathogenic’ at mucosal surfaces because they secrete candidalysin; a pore-forming peptide toxin that causes tissue damage, inflammation, and symptomology. To produce candidalysin, C. albicans must express a gene called ECE1. Once expressed, the Ece1 protein is processed into eight small peptides, the third of which is candidalysin. Importantly, efficient processing of Ece1 is context-dependent, and essential for candidalysin production, while the amino acid sequence of candidalysin is also critical for toxicity and potency. However, while candidalysin secretion is critical for pathogenicity, it is only the final step in a carefully regulated cascade of events that are required for full C. albicans virulence, including adhesion; invasion; hyphal maintenance; ECE1 expression, and candidalysin processing and secretion.
Numerous studies have catalogued the fungal...
Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start FreeSolicitation Details
| Issuing agency | BBSRC |
|---|---|
| Country | United Kingdom |
| Category | Research Development |
| Published | May 31, 2025 |
| Procurement stage | Active solicitation |
| Closed | Closing date not published |
| Status | Closed — no longer accepting responses |
| Official source | View original notice |
| Last verified | October 10, 2026 |
Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.
Browse Similar Open Opportunities in United Kingdom
See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →Get a free United Kingdom Research Development intelligence report in your inbox
A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.